The New England journal of medicine 2013-04-04
Hepatotoxicity with combination of vemurafenib and ipilimumab.
Related Questions
Do you ever consider bridging with chemotherapy, and if so for how long?
New answer by Medical Oncologist at Roswell Park Comprehensive Cancer Center (June 28, 2023)
In general, one should be cautious. Phenomenon of increased toxicity with immune checkpoint inhibitors (ICIs) plus targeted therapies such as EGFR TKI (pneumonitis, hepat...